Sandoz Acquisitions Will Contribute $1.3 Bil. To 2005 Sales, Novartis Says
Executive Summary
The integration of the generic drug makers Hexal and Eon Labs into Novartis' Sandoz unit is proceeding ahead of schedule, Novartis reported
You may also be interested in...
Novartis’ “Captainship” Program Produces More Hypertension Market Share
Nearly a year after introducing its "category captainship" strategy to enhance its leadership position in the market, Novartis is reporting its most successful quarter in the hypertension market
Novartis’ “Captainship” Program Produces More Hypertension Market Share
Nearly a year after introducing its "category captainship" strategy to enhance its leadership position in the market, Novartis is reporting its most successful quarter in the hypertension market
Novartis’ New Vaccine Division Takes On Evolving Market
Novartis' newly acquired vaccines unit will face an increasingly differentiated market for flu vaccines, Vaccine & Diagnostic Business CEO Jörg Reinhardt said